Regenxbio (RGNX) Long-Term Investments (2014 - 2025)

Regenxbio's Long-Term Investments history runs 12 years deep, the most recent figure standing at $10.8 million for Q4 2025.

• On a quarterly basis, Long-Term Investments rose 5.95% year-over-year to $10.8 million in Q4 2025; TTM through Dec 2025 was $10.8 million, a 5.95% increase from a year earlier, with the FY2025 full-year figure at $10.8 million, up 5.95% from the prior year.
• Long-Term Investments eased to $10.8 million in Q4 2025 per RGNX's latest filing, from $27.8 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $391.9 million in Q4 2021 and bottomed at $4.9 million in Q1 2025.
• The 5-year median for Long-Term Investments is $79.0 million (2023), against an average of $131.9 million.
• Across the five-year window, Long-Term Investments surged 737.25% in 2021 and tumbled 88.38% in 2025, its largest moves.
• Year by year, Long-Term Investments stood at $391.9 million in 2021, then slumped by 48.82% to $200.6 million in 2022, then tumbled by 80.62% to $38.9 million in 2023, then slumped by 73.81% to $10.2 million in 2024, then increased by 5.95% to $10.8 million in 2025.
• Per Business Quant, the three latest RGNX Long-Term Investments figures stand at $10.8 million (Q4 2025), $27.8 million (Q3 2025), and $40.3 million (Q2 2025).